Fig. 6: Blocking IGF1R signaling by pharmacological inhibitors prevents gemcitabine-induced CD44 isoform switching and EMT. | Cell Death & Disease

Fig. 6: Blocking IGF1R signaling by pharmacological inhibitors prevents gemcitabine-induced CD44 isoform switching and EMT.

From: Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching

Fig. 6

a GS cells were treated with the doses of gemcitabine increased weekly (up to 800 ng/ml) and a constant dose of inhibitors (50 nM OSI-906; 10 μM LY294002; 5 μM U0126). Cell lysates were analyzed by Western blot with indicated antibodies. b RT-PCR analysis of CD44s and CD44v, primers were same as in Fig. 1c. c Invasion assay performed with the cells from the above treatment (gemcitabine 800 ng/ml). Invaded cells were stained and counted under the light microscope. Data were represented as mean ± SD performed in triplicate. d Cell proliferation rate was performed with the cells that survived from above treatments by MTT assay and the data were represented as mean ± SD in four replicates. The percentage of cell growth for each treatment compared to control at 100 ng/ml gemcitabine is presented. Statistical analysis by two-way ANOVA was shown in the table.

Back to article page